Introduction
Cytochrome P450 (CYP) 2A6 is the primary enzyme involved in the oxidative metabolism of nicotine and clinically useful drugs such as metronidazole, methoxyflurane, tegafur, valproic acid, and fadrozole (Kharasch et al., 1995; Nakajima et al., 1996; Sadeque et al., 1997; Komatsu et al., 2000; Pelkonen et al., 2000; Pearce et al., 2013) . This enzyme also plays an important role in the metabolic activation of 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosodiethylamine (NNN), major constituents in tobacco smoke (Crespi et al., 1991) .
Nicotine, the main driver in the development and maintenance of tobacco dependence, is primarily metabolized to cotinine (70-80%) by CYP2A6 ( Fig. 1 ) (Benowitz et al., 1995; Fagerstrom and Balfour, 2006) . A phenotype study using nicotine as the CYP2A6 probe substrate discovered significant individual variability in CYP2A6 activity (Nakajima et al., 2006) . A meta-analysis suggested that reduced metabolizers (patients with low CYP2A6 activity) smoke fewer cigarettes per day than normal metabolizers (Pan et al., 2015) . The presence of several CYP2A6 variants explained as to why large deviation fractions where observed in estimated nicotine biomarker metabolism rates, identified in a genome-wide association study (Loukola et al., 2015) . Furthermore,
but also with the effect that causes smokers to smoke more extensively (Patel et al., 2016) . Tegafur, a prodrug of 5-fluoroulacil (5-FU), is another clinically important CYP2A6 substrate in human liver microsomes (Yamamiya et al., 2014) . CYP2A6
enzymatic activity variation would affect the therapeutic effect through 5-FU biokinetics.
Investigating the enzymatic functions of individual CYP2A6 allelic variants in vivo is difficult being that the number of patients carrying low-frequency alleles is limited (Soriano et al., 2011) . Therefore, in vitro characterization of CYP2A6 variants activity, using a recombinant enzyme system is essential for a deeper understanding of the individual variability in drug response and toxicity. Various heterologous expression systems, including bacteria, yeast, insect cells, and mammalian cells, have been used in previous studies (Hiratsuka, 2012) . Through the use of these systems, several CYP2A6
variants have been found to exhibit reduced catalytic activities toward various CYP2A6
substrates compared with that of the wild type, CYP2A6.1 (Kitagawa et al., 2001; Daigo et al., 2002; Han et al., 2012; Yamamiya et al., 2014) . However, these studies assessed different kinetic parameters (K m , V max , and CL int ). In addition, posttranslational processing of proteins expressed in bacteria, yeast, and baculoviruses differs from that in mammalian cells (Oldham, 1998; Hirathuka, 2012) . Such differences in expression
systems may result in discrepancies in findings and conclusions.
A large number of genetic polymorphisms in the CYP2A6 gene have been identified in several ethnic groups and shown to contribute to altered enzyme activation and expression (Fernandez-Salguero et al., 1995; Oscarson et al., 1999; Kiyotani et al., 2002; Haberl et al., 2005; Al Koudsi et al., 2009; Piliguian et al., 2014) . These polymorphisms are thought to produce individual variations in pharmacokinetics, drug efficacy, adverse drug reactions, and drug toxicities (Fujieda et al., 2004; Wang et al., 2011; Yamamiya et al., 2014; Hosono et al., 2015; Kumondai et al., 2016 for CYP2A6 to determine whether the observed functional changes were substrate-dependent (Miles et al., 1990) .
Materials and Methods

Chemicals
(-)-Nicotine, (-)-cotinine, and (±)-cotinine-(methyl-d3) derivatives, as well as coumarin, 7-hydroxycoumarin, and 4-methyl-7-hydroxycoumarin were purchased from Sigma-Aldrich (Tokyo, Japan 
Determination of protein expression levels by immunoblotting
We separated 293FT microsomal fractions (4 μ g of microsomal protein) by
1 1 electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels. Western blotting was performed in triplicate for each CYP2A6 variant protein in accordance with standard procedures. Recombinant CYP2A6 supersome was used as the standard (0.06-0.50 pmol) in each gel to quantify the CYP2A6 protein level. CYP2A6 protein was detected using a polyclonal anti-human CYP2A6 antibody (diluted at 1:10,000), and calnexin, used as a loading control, was detected using a polyclonal anti-calnexin antibody (diluted at 1:5000). Secondary detection was carried out with horseradish peroxidase-conjugated goat anti-rabbit IgG (diluted at 1:10,000). Immunoblots were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). Chemiluminescence was quantified using a ChemiDoc XRS + with the help of Image Lab Software (Bio-Rad Laboratories).
Nicotine C-oxidation assay
Nicotine C-oxidation by CYP2A6 was measured as reported previously (Nakajima et al., 1996) and collision pressure, 1.7 mTorr. The sheath gas was nitrogen, and the collision gas was argon. The LC-MS/MS system was controlled by Xcalibur software (Thermo Fisher Scientific), which was also used to analyze the data. The lower limit of cotinine quantification was 10 nM. Standard curves for cotinine were constructed in the 0.01-30 μ M range using authentic metabolite standards. The enzymatic activity was normalized to the corresponding CYP2A6 expression level.
Coumarin 7-hydroxylation assay
The coumarin 7-hydroxylation activity of CYP2A6 was determined using 
Data analysis
The kinetic data were analyzed using the Enzyme Kinetics Module of The correlation between the CL int ratios of nicotine C-oxidation and coumarin 7-hydroxylation among CYP2A6 variants was analyzed using weighted linear regression analysis (IBM SPSS Statistics). Differences or correlations with P-values of less than 0.05 were defined as significant.
Three-dimensional structural modeling of CYP2A6
Three-dimensional (3D) structural modeling of CYP2A6 and nicotine binding 
Results
Protein levels of CYP2A6 variants expressed in 293FT cells were measured by immunoblotting. Polyclonal CYP2A6 antibodies recognized all CYP2A6 variant proteins (Fig. 2) . Only CYP2A6.13 exhibited a double band, the bands at both molecular weights were quantified. Expression levels for calnexin, an endoplasmic reticulum-resident protein, were virtually constant in the microsomes of transfected cells. CYP2A6 protein was not detected in cells transfected with empty vector (mock transfection).
The kinetic parameters of nicotine C-oxidation were determined for the wild type (CYP2A6.1) and 26 CYP2A6 variants ( amino acid substitution, was found in African-American subjects with a frequency of 9.4% (Fukami et al., 2004) .
The substituted residue is located in the substrate recognition site (SRS)-5, some of these amino acid chains form the heme pocket. CYP2A6*25 and CYP2A6*26 were identified in an African population and include the Phe118Leu substitution . The nicotine metabolic activities for these variants were reduced to 90% when expressed in Escherichia coli cells (CYP2A6*25) and to 0% (CYP2A6*26) for the wild-type. Phe118 is situated in SRS-1 and is predicted to be involved in substrate stability. Moreover, CYP2A6*26 contains the Arg128Leu substitution, which is thought to be related to holoprotein formation. CYP2A6*35, CYP2A6*36, and CYP2A6*37 were also discovered in an African population
2 2 Al Koudsi et al., 2009 ). These variant alleles include Asn438Tyr, caused by the 6458A>T mutation. Asn438 is located in a heme binding site, suggesting the possibility that the amino acid substitution alters the binding stability of heme. CYP2A6*43 (4406C>T, Thr303Ile) was identified in African Americans, and its catalytic efficiency was reported to be reduced compared to that of CYP2A6.1 (Piliguian et al., 2014) . Thr303 is positioned in SRS-4, and its substitution may negatively impact function and stability. Thus, these mutations in highly conserved CYP regions may affect enzyme activity by altering the stability of the enzyme and/or its affinity to substrates and heme. However, the quantitative protein expression levels differ between CYP2A6 variants due to alterations in protein stability caused by amino acid replacement variations (Fig 4) . However, it is the limitation of this study that the transfection efficiency for expressing CYP2A6 protein was not evaluated.
The CYP2A6*7 allele contains a 6558T>C nucleotide substitution causing the Ile471Thr substitution in the β 4(1) strand near SRS-6; this substitution is known to decrease the catalytic activity of the enzyme (Ariyoshi et al., 2001; Uno et al., 2013) .
This amino acid may be involved in determining the conformation of SRS-6. In our study, CYP2A6.8, including the Arg485Leu substitution, exhibited reduced enzymatic activity. This substitution also occurs near SRS-6 and may alter the folding of SRS-6
2 3 (Ariyoshi et al., 2001 ). Both of the above amino acid changes are also included in several other variant alleles (CYP2A6*10, CYP2A6*19, CYP2A6*36, and CYP2A6*37) and are likely to affect the enzymatic activities for these alleles as well. For CYP2A6*13, two protein bands were detected by immunoblotting. The Gly5Arg amino acid substitution in CYP2A6.13, occurring in the membrane anchor region, may alter the protein's digestion by proteases explaining the additional band. Further studies are needed to confirm these findings.
The 1703G>A single point mutation in CYP2A6*6 leads to the Arg128Gln substitution, which is present in the Japanese population with a frequency of 0.4% (Kitagawa et al., 2001) . The Arg128 residue is located in a highly conserved region of the CYP superfamily and results in a reduced CO difference spectrum for hemin-fortified CYP2A6.6 compared with that of the wild-type enzyme. In the 3D structure model of the human CYP2A6, this residue forms hydrogen bonds with Asn438, which is located next to the heme-binding Cys439 (Fig. 5) . By eliminating this hydrogen bond, the Arg128Gln substitution may affect the binding of heme and disorder the holoprotein structure. The CYP2A6*11 allele (3391T>C, Ser224Pro) was identified in a Japanese patient exhibiting a high plasma tegafur concentration-time curve (Daigo et al., 2002) . According to our analysis, the coumarin 7-hydroxylation activity of proteins were separated by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels and then subjected to western blotting according to standard procedures. The CYP2A6 variant proteins were detected using a polyclonal antibody against CYP2A6 and calnexin was detected using a polyclonal antibody against calnexin. Numbers correspond to CYP2A6 variants. These data represent the mean ± SD of three independently performed catalytic assays.
*P < 0.05, **P < 0.01, and ***P < 0.005 compared to CYP2A6.1. N.D. represents not determined.
The kinetic parameters for nicotine C-oxidation of CYP2A6.2, CYP2A6.5, CYP2A6.6, and CYP2A6.26 could not be determined because the enzymatic activity of CYP was not detected at the highest substrate concentration (1000 μ M nicotine).
The kinetic parameters for nicotine C-oxidation of CYP2A6.10, CYP2A6.36, and CYP2A6.37 could not be determined because the amount of product, cotinine, produced by these variants was below the quantification limit at low substrate concentrations.
The kinetic parameters of CYP2A6.2, CYP2A6.5, CYP2A6.6, CYP2A6.26, and CYP2A6.37 could not be determined because the enzymatic activity of CYP was not detected at the highest substrate concentration (25 μ M coumarin).
The kinetic parameters for nicotine C-oxidation of CYP2A6.10, CYP2A6.25, CYP2A6.36, and CYP2A6.44 could not be determined because the amount of product, 7-hydroxycoumarin, produced by these variants was below the quantification limit at low substrate concentrations.
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